论文部分内容阅读
[目的]评价拉米呋定预防肿瘤患者化疗后乙型肝炎发作的作用。[方法]60例肿瘤患者合并HBV感染者,对照组30例未接受拉米呋定预防治疗,只接受常规保肝、降酶治疗。治疗组30例:除常规保肝、降酶治疗外,加用拉米呋定片100mg/d,从化疗前1周开始服用至化疗结束后6个月。[结果]治疗组HBV-DNA水平逐渐下降,而对照组HBV-DNA水平逐渐升高。对照组ALT峰值显著高于治疗组。[结论]拉米呋定能预防恶性肿瘤合并乙型肝炎感染者化疗后肝炎病毒的激活。
[Objective] To evaluate the effect of lamivudine in preventing the onset of hepatitis B after chemotherapy in cancer patients. [Method] Sixty patients with tumor were infected with HBV. 30 patients in the control group did not receive lamivudine prophylaxis and only received routine liver protection and enzyme-lowering therapy. Treatment group of 30 patients: In addition to conventional liver, reducing enzyme treatment, plus lamivudine tablets 100mg / d, starting from 1 week before chemotherapy to 6 months after the end of chemotherapy. [Results] The level of HBV-DNA in treatment group decreased gradually, while the level of HBV-DNA in control group increased gradually. ALT peak value in the control group was significantly higher than that in the treatment group. [Conclusion] Lamivudine can prevent the activation of hepatitis virus after chemotherapy in patients with malignant tumor and hepatitis B infection.